Potential third-party radiation exposure from outpatients treated with 131I for hyperthyroidism

Medical Physics

Volumn 31, Issue 12, 2004, Pages 3194-3200

  Matheoud, Roberta ^a   Reschini, Eugenio ^a   Canzi, Cristina ^a   Voltini, Franco ^a   Gerundini, Paolo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Hyperthyroidism; Radiation protection; Radioiodine

Indexed keywords

CURVE FITTING; PATIENT MONITORING; RADIATION PROTECTION; SLEEP RESEARCH;

BI-EXPONENTIAL FUNCTIONS; EFFECTIVE DOSE RATE; EUROPEAN COMMISSION; HYPERTHYROIDISM; RADIATION EXPOSURE; RADIOIODINE; RADIOIODINE TREATMENT; RISK OF CONTAMINATION;

PATIENT TREATMENT;

IODINE 131;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSIMETRY; HEALTH HAZARD; HUMAN; HYPERTHYROIDISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; SWEATING;

EID: 11244266134     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1809781     Document Type: Article

References (25)

1. D. S. Ross, E. C. Ridgway, and G. H. Daniels, "Successful treatment of solitary toxic thyroid nodules with relatively low-effective dose iodine-131, with low prevalence of hypothyroidism," Ann. Intern Med. 101, 488-490 (1984).
2. 131I therapy of solitary autonomous thyroid nodules: Effect on thyroid size and early hypothyroidism," Acta Endocrinol. 113, 226-232 (1986).
3. D. A. Huysmans, F. H. Corstens, and P. W. Kloppenborg, "Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine," J. Nucl. Med. 32, 27-30 (1991).
4. C. Reiners and P. Shneider, "Radioiodine therapy of thyroid autonomy," Eur. J. Nucl. Med. 29(Suppl. 2), S471-478 (2002).
5. 99mTc-pertechnetate thyroid uptake," Eur. J. Nucl. Med. 29, 480-485 (2002).
6. R. C. T. Buchan and J. M. Brindle, "Radioiodine therapy to out-patients - the contamination hazard," Br. J. Radiol. 43, 479-482 (1970).
7. 131I," Health Phys. 76, 129-136 (1999).
8. E. Ibis, C. R. Wilson, D. Collier, G. Akansel, A. T. Isitman, and R. G. Yoss, "Iodine-131 contamination from thyroid cancer patients," J. Nucl. Med. 33, 2110-2115 (1992).
9. 131I therapy for thyrotoxicosis," Nucl. Med. Commun. 14, 160-168 (1993).
10. M. Monsieur, H. Thierens, R. A. Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De Saedeleer, H. De Winter, M. Lippens, S. van Imschoot, D. Wulfrank, and M. Simons, "Real life radiation burden to relatives of patients treated with iodine-131: A study in eight centres in Flanders (Belgium)," Eur. J. Nucl. Med. 25, 1368-1376 (1998).
11. S. F. Barrington, M. J. O'Doherty, A. G. Kettle, W. H. Thomson, P. J. Mountford, D. N. Burrell, R. J. Farrell, S. Batchelor, P. Seed, and L. K. Harding, "Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism," Eur. J. Nucl. Med. 26, 686-692 (1999).
12. 131I therapy. Measured effective doses in family members," Health Phys. 76, 129-136 (1999).
13. Council of the European Union. Directive on the Health Protection of Individuals against the dangers of ionizing radiation in relation to medical exposure, 97/43/Euratom OJ L180, 22-27 (1997).
14. European Commission. Radiation Protection 97. Radiation protection following Iodine-131 therapy (exposures due to out-patients or discharged in-patients). Luxembourg, Office for Official Publications of the European Communities, 1998.
15. 131I therapy in Europe," Thyroid 7, 221-224 (1997).
16. C. M. Culver and H. J. Dworkin, "Radiation safety considerations for post-iodine-131 thyroid cancer therapy," J. Nucl. Med. 33, 1402-1405 (1992).
17. E. Reschini, R. Matheoud, C. Canzi, M. Castellani, M. Galelli, C. Ferrari, A. Paracchi, and P. Gerundini, "Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy," J. Nucl. Med. 40, 1928-1934 (1999).
18. R. Matheoud, C. Canzi, E. Reschini, F. Zito, F. Voltini, and P. Gerundini, "Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule," Med. Phys. 30, 791-798 (2003).
19. A. Bockish, T. Jamitzky, R. Derwanz, and H. J. Biersack, "Optimized effective dose planning of radioiodine therapy of benign thyroidal diseases," J. Nucl. Med. 34, 1632-1638 (1993).
20. J. A. Siegel, C. S. Marcus, and R. B. Sparks, "Calculating the absorbed effective dose from radioactive patients: The line source versus point-source model," J. Nucl. Med. 43, 1241-1244 (2002).
21. A. D. Wrixon, G. S. Linsley, K. C. Binns, and D. F. White, "Derived limits for surface contamination," NRPB-DL2, November 1979, Harwell, Didcot, Oxon, OX11 ORQ.
22. International Commission on Radiation Protection n.60, Recommendations of the International Commission on Radiological Protection, Vol. 21, No. 1-3 (Pergamon, Oxford, 1992).
23. P. B. Zanzonico, J. A. Siegel, and J. St. Germain, "A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy," Health Phys. 78, 648-659 (2000).
24. National Council on Radiation Protection and Measurements Commentary n.11, "Effective dose limits for individuals who receive exposure from radionuclide therapy patients," Bethesda, MD, 1995.
25. International Commission on Radiation Protection n.68, Effective Dose Coefficients for Intakes of Radionudides by Workers, Vol. 24, No. 4 (Pergamon, Oxford, 1994).